Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2021 · 10-Q
Revenue$167.30M$167.30M+15.2% vs Q3 2020 Net Income$24.60M$24.60MN/M vs Q3 2020 EPS Diluted$0.30$0.30N/M vs Q3 2020 Operating Income-$79,900,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$42,300,000N/M Margins · derivedOperating margin-47.8%−20.5 pt vs Q3 2020
Net margin14.7%+25.2 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end